>Receptor Tyrosine Kinases
>Human VEGF R2 / KDR / CD309 Protein, His Tag (HPLC-verified)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 85.2 kDa. The protein migrates as 125-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
Human VEGF R2, His Tag (HPLC-verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human VEGF R2, His Tag (HPLC-verified) (Cat. No. KDR-H5227) was greater than 90% as determined by SEC-HPLC.
Immobilized Human VEGF R2, His Tag (HPLC-verified) (Cat. No. KDR-H5227) at 2 μg/mL (100 μL/well), can bind pre-mixed increasing concentrations of Bevacizumab and 0.05 μg/mL (100 μL/well) Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a half maximal inhibitory concentration (IC50) of 0.74 μg/mL (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $290.00
Price(USD) : $1800.00
This web search service is supported by Google Inc.